Evidence map›Paper›PMID 40994670›Full record

ReviewFrontiers in bioengineering and biotechnology2025

Biomimetic erythrocyte-based drug delivery systems for organ-targeted therapy.

Kehui Zhu, Yike Huang, Keying Li, Ke Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Beyond autologousMolecular therapy. Oncology · 2026
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kehui Zhu *Department of Blood Transfusion, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Yike Huang *Department of Laboratory Medicine, Clinical Laboratory Medicine Research Center, West China Hospital, Sichuan University, Sichuan Clinical Research Center for Laboratory Medicine, Chengdu, China.
Keying LiDepartment of Blood Transfusion, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Ke ZhangDepartment of Blood Transfusion, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Enhancing drug accumulation in target organs while minimizing adverse effects is critical for pharmacological therapies. Therefore, the development of advanced drug-targeting platforms is essential for clinical application. These systems must not only enable precise organ-specific targeting but also improve drug bioavailability and extend systemic circulation. In recent years, significant progress has been made in blood cell-inspired drug delivery strategies, with red blood cells-based (RBCs-based) platforms showing particular promise due to their inherent physiological advantages. Nevertheless, the development of organ-specific RBCs-mediated delivery systems remains challenging. We categorize and summarize various drug loading methods for existing RBCs, along with their advantages, disadvantages, and treated disease types. We then focus on describing various design strategies of RBCs-based delivery systems targeting specific organs and review their current applications. Additionally, we discuss current challenges and future perspectives regarding RBCs-based targeted delivery platforms.

Indexed as

cell drug deliverycell therapeuticdrug delivery system (DDS)organ targetingred blood cells(RBCs)

Identifiers

PMID40994670
PMCPMC12455729

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.